Elevating Precision Oncology
To help advance precision oncology, it is critical to identify the molecular changes that underlay tumorigenesis in solid tumors.
This webinar describes a new hybrid-capture target enrichment, next-generation sequencing (NGS) assay, run on the MGI DNBSEQ-G400 Sequencer and analyzed using SOPHiA GENETICS DDM™, that provides a modular and flexible approach to tumor characterization.
Presenter: Felicity Hall, Ph.D. (NGS Product Manager, Agilent Technologies)
Felicity Hall is the Sr Global Product Manager for SureSelect Cancer Assays at Agilent Technologies. Felicity received her PhD in Molecular Biology from Monash University in Australia. Felicity has worked with market-leading global genomics companies and her expertise is diverse, spanning both Clinical Genomics and Life Science Genomics markets.
Presenter: Michael Ruvolo, Ph.D. (Director, R&D, Agilent Technologies)
Mike is the director of NGS content development at Agilent Technologies. He and his team are responsible for assay development using SureSelect NGS target enrichment technology.
